Treatment of epidermoid anal canal cancer

Salmon, Rémy; Fenton, J.; Asselain, Bernard; Mathieu, G; Girodet, J; Durand, Jean Claude; Decroix, Y; Pilleron, J P; Rousseau, Jean

doi:10.1016/0002-9610(84)90032-1

Cited by 103 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the past, abdominoperineal resection (APR) was the standard treatment, obtaining 5-year overall survival rates of about 50%, mostly due to local relapse [3][4][5][6]. Several studies have shown the curative effect of external beam radiotherapy (RT), alone or in combination with interstitial techniques, with 5-year survival comparable to surgery [7][8][9][10][11][12][13][14]. Combined chemoradiotherapy (CRT), first reported by Nigro et al [15], has been widely used to improve survival and sphincter preservation.…”

Section: Introductionmentioning

confidence: 99%

Role of Dose Intensity in Conservative Treatment ofAnal Canal Carcinoma

Ceresoli¹,

Ferreri²,

Cordio³

et al. 1998

Oncology

View full text Add to dashboard Cite

Chemoradiotherapy (CRT) is considered the standard treatment for anal canal cancer. However, the optimum schedule of therapy has yet to be defined. This study was carried out to evaluate the role of dose intensity (DI) of chemotherapy (ChT) and radiotherapy (RT) on the outcome of patients submitted to CRT. Thirty-five consecutive patients with anal canal carcinoma received a combination of RT (median dose 56 Gy) and ChT (two or more cycles of 5-fluorouracil and mitomycin C). With a median follow-up of 33 months, 83% of patients are alive without evidence of disease and 70% are colostomy-free. Five-year actuarial disease-free survival (DFS) is 74%. Univariate and multivariate analysis was performed to determine the correlation of DFS with various clinical and therapeutic parameters. Our series confirmed the prognostic negative value of a tumor size >4 cm. An average relative dose-intensity (ARDI) >0.8 was related to a better outcome both in univariate and in multivariate analysis; an overall treatment time >70 days was related to a worse DFS in univariate analysis, but these data were not confirmed by the Cox model. RT dose was not associated with DFS. In conclusion, the results of this study seem to suggest an independent prognostic role of ChT DI, as measured by ARDI. The results regarding RT DI are inconclusive, and remain a matter for further trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of Dose Intensity in Conservative Treatment ofAnal Canal Carcinoma

Ceresoli¹,

Ferreri²,

Cordio³

et al. 1998

Oncology

View full text Add to dashboard Cite

show abstract

“…We noted that some studies, for example, that of Salmon et al 23 with a last year of patient enrolment at 1979 might be an outlier. We repeated the meta-regressions of LNP versus median study year, excluding one study at a time, and found similar results (webappendix p41).…”

Section: Sensitivity Analysesmentioning

confidence: 88%

“…Excluded studies and reasons for exclusion are detailed in webappendix p16-24. Forty-five studies contributed to analyses of 5-year OS; 11 studies to ; and institution-level treatment series [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] . Median follow-up periods ranged from 1.3 to 8.6 years.…”

Section: Included Studiesmentioning

confidence: 99%

Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study

Sekhar

Zwahlen

Trelle

et al. 2017

The Lancet Oncology

View full text Add to dashboard Cite

“…Traditionally, anal cancer had been a disease of older women, with onset in the 7 th decade of life, and a female to male predominance of up to 5 to 1 (3,4). However, with the increasing HIV epidemic, there has been an increase in the number of younger men affected with the disease.…”

Section: Epidemiology and Risk Factorsmentioning

confidence: 99%